Compounds > cardiotensin
Page last updated: 2024-12-08

cardiotensin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID195878
MeSH IDM0084440

Synonyms (4)

Synonym
cardiotensin
75934-75-7
bemetizide, bupranolol, triamterene drug combination
2h-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(1-phenylethyl)-, 1,1-dioxide, mixt. with 1-(2-chloro-5-methylphenoxy)-3-((1,1-dimethylethyl)amino)-2-propanol hydrochloride and 6-phenyl-2,4,7-pteridinetriamine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.08 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (19.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (40.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uric acid
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.		3.3411uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
bupranolol
Bupranolol: An adrenergic-beta-2 antagonist that has been used for cardiac arrhythmia, angina pectoris, hypertension, glaucoma, and as an antithrombotic.		6.23104aromatic ether
triamterene
Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.		6.23104pteridinesdiuretic;
sodium channel blocker
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High
[description not available]		06.23104
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		06.23104
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.3411
Milk-Alkali Syndrome
[description not available]		03.3411
Hypercalcemia
Abnormally high level of calcium in the blood.		03.3411
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		03.3411